Health and Medical Guide to Diagnostic Tests Diagnostic Tests Health information topics about Diagnostic Tests: Amniocentesis (Prenatal Testing) Blood Tests (Laboratory Tests) CAT Scans (CT Scans) Chorionic Villi Sampling (Prenatal Testing) CT Scans (CT Scans) Diagnostic Imaging (Diagnostic Imaging) Echocardiography (Ultrasound) Fetal Ultrasound (Prenatal Testing) Genetic Testing (Genetic Testing) Laboratory Tests (Laboratory Tests) Magnetic Resonance Imaging (MRI Scans) Mammography (Mammography) MRI Scans (MRI Scans) Nuclear Scans (Nuclear Scans) Paternity Testing (Genetic Testing) PET Scans (Nuclear Scans) Prenatal Testing (Prenatal Testing) Radiography (X-Rays) Radionuclide Scans (Nuclear Scans) Ultrasound (Ultrasound) Urine Tests (Laboratory Tests) X-Rays (X-Rays)   Clinical Trials / Drug Trials News From Medical News Today Latest Health News and Medical News posted throughout the day, every day. FDA Approves Embryonic Stem Cell-Based Therapy For Patients With Acute Spinal... 31 Jul 2010 at 9:00am The US FDA (Food and Drug Administration) has lifted a clinical hold on Geron's Investigational New Drug (IND) application - the Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may now go ahead. GRNOPC1 is the first ever clinical trial of a human embryonic stem cell based therapy in humans... Biogen Idec And Swedish Orphan Biovitrum Present Data On Long-Lasting Hemophi... 31 Jul 2010 at 3:00am Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (STO: SOBI) announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients... Orexigen® Therapeutics Announces Publication Of COR-I Phase 3 Study Of Contra... 30 Jul 2010 at 4:00am Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave® were published online in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration... Intra-Cellular Therapies Announces The Successful Completion Of A Phase Ib/II... 30 Jul 2010 at 3:00am Intra-Cellular Therapies, Inc. announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia... ANA598 Demonstrates SVR12 In 100% Of First Group Of HCV Patients Randomized T... 30 Jul 2010 at 3:00am Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12... Bionovo To Advance Menerba To Phase 3 Clinical Testing In Europe 30 Jul 2010 at 3:00am Bionovo, Inc. (Nasdaq: BNVI) announced that it has received final guidance from the European Medicines Agency (EMA) in order to advance Menerba, the company's lead drug candidate for menopausal symptoms, to Phase 3 clinical trials in Europe. The guidance defines the clinical and regulatory pathway to a European marketing authorization for Menerba... ArQule Announces Initiation By Kyowa Hakko Kirin Of Phase 2 Clinical Trial In... 30 Jul 2010 at 2:00am ArQule, Inc. (Nasdaq: ARQL) announced the initiation of a Phase 2, single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin, its exclusive licensee for the development and commercialization of ARQ 197 in the Asian territory consisting of Japan, China (including Hong Kong), South Korea and Taiwan... ACT Files Documentation With FDA For Clinical Trials Using ES Cells To Treat ... 29 Jul 2010 at 2:00pm Advanced Cell Technology, Inc... Etubics Enters Phase I Cancer Clinical Trials Focused On Colorectal Cancer 29 Jul 2010 at 10:00am Etubics Corporation, a biopharmaceutical company developing "next generation" vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen (CEA)-expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S... Advaxis Phase I Survival Update 29 Jul 2010 at 8:00am Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy... New England Journal Of Medicine Publishes Data From Pivotal Phase 3 PROVENGE ... 29 Jul 2010 at 4:00am Dendreon Corporation (Nasdaq: DNDN) announced the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE® (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC)... Teva Respiratory Announces Positive Results From Phase III Trial Of BDP HFA N... 29 Jul 2010 at 4:00am Teva Respiratory announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo... Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial Of PSI-9... 29 Jul 2010 at 4:00am Pharmasset, Inc. (Nasdaq: VRUS) announced that safety and pharmacokinetic data from the PSI-352938 ("PSI-938") single ascending dose study support progression to a multiple ascending dose trial with PSI-938, which has initiated dosing. PSI-938 is a guanine nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection... Angiotech Pharmaceuticals And Partner Athersys Announce Positive Results From... 29 Jul 2010 at 4:00am Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) announced positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack... Curemark Opens Autism Trials At New Jersey Site 29 Jul 2010 at 4:00am Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment. Saint Peter's is affiliated with the Drexel University College of Medicine in Philadelphia...     HealthBusinessBuilder.com Build your Health Business Fast!